Another study enrolled 14 patients with R/R lymphoma to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and clinical responses of IMM01 (SIRPα-IgG 1 fusion protein) [109]. This evidence concerns the gene SIRPA and lymphoma.